AbbVie Inc.
Prices may be delayed up to 20 min. Not investment advice. News volume: articles about it in the 4Search index. Click a dot on the chart for the event and the news of that day.
Key statistics
Against its peers
Compare in full ›| ABBV.BA | BMY | 0QYQ.IL | PFE | BIIB | ABVC | |
|---|---|---|---|---|---|---|
| Market cap | 91.30T | 120.19B | 209.33B | 156.18B | 36.89B | 23.37M |
| P/E (TTM) | 6.1 | 13.0 | 38.6 | 39.1 | 108.0 | — |
| Forward P/E | — | 8.8 | — | 9.3 | 15.4 | -2.0 |
| Price/book | -13.0 | 5.1 | 9.9 | 1.8 | 1.9 | 1.7 |
| Dividend yield | 2.31% | 4.29% | 3.81% | 6.28% | — | — |
| 1-year change | +38.07% | +23.12% | +35.35% | +8.64% | +41.15% | −67.29% |
| Today | +5.07% | +0.79% | +0.60% | −0.51% | +1.00% | −1.56% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 20 min.
Latest news
All ABBV.BA news ›$500,000 in AbbVie and Gilead Could Pay More Than $11,000 a Year in Dividends
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare,…
AbbVie (ABBV) Stock Just Got a 5.2% Dividend Increase. Here's How Many Shares You Need to Generate $1,000 a Year.
This pharmaceutical giant has hiked its payout for 53 years in a row, so it's likely to keep doing so. Key Points AbbVie's dividend yield of 2.4% is solid, but more importantly, it's been growing at an impressive clip. The stock isn't…
AbbVie bets on dual-target cancer therapies in Disco research deal
Therapy Area Allergy & Immunology Cardiology Dermatology Diabetes Flagship Journal Gastroenterology General Healthcare Hematology Hepatology Innovations Interventional Cardiology Microbiology & Infectious Diseases Nephrology Neurology…
AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy for 2027?
Eli Lilly's revenue is climbing at a pace AbbVie can't match, yet AbbVie trades at a noticeably lower earnings multiple. Key Points AbbVie generates significant cash flow from its newer immunology stars, Skyrizi and Rinvoq. Eli Lilly is…
AbbVie Advances ABBV-2294 Study for Rare Systemic Sclerosis
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer. Tipranks - Thu Nov 19, 10:35AM CST Abbvie (ABBV) announced an…
AbbVie Is Up 27% in a Year. Barclays Sees Another 14%
Key Takeaways Barclays raised its AbbVie price target to $335 from $325 on Nov. 16 and kept its Overweight rating, after a run that has the stock up 27% in a year. AbbVie’s third quarter backed the bulls: revenue rose 10.3%, Skyrizi and…
AbbVie Is Near Its High. Piper Sandler Sees Another 23%
Key Takeaways Piper Sandler raised its AbbVie price target to $349 from $303 and kept its Overweight rating, 23% above the Nov. 19 close of $283.54. Piper argues AbbVie deserves a higher multiple, partly on early data for Skyrizi…
AbbVie makes Formula 1 debut with McLaren
Therapy Area Allergy & Immunology Cardiology Dermatology Diabetes Flagship Journal Gastroenterology General Healthcare Hematology Hepatology Innovations Interventional Cardiology Microbiology & Infectious Diseases Nephrology Neurology…
Abbott Laboratories (NYSE: ABT), AbbVie (NYSE: ABBV), And Coca-Cola (NYSE: KO) Stand Out As Elite Dividend Compounders Built To Last
Abbott Laboratories (NYSE: ABT) made headlines this year after closing a $21 billion cash deal to acquire Exact Sciences, a company focused on cancer diagnostics. The acquisition targets one of Abbott’s slower-growing business units and…
DISCO Pharmaceuticals Announces Strategic Collaboration with AbbVie to Advance Next-Generation AND-Gated Bispecific Therapeutics for Solid Tumors
The collaboration leverages DISCO’s proprietary DISCOtech® surfaceome mapping platform and AND-gated bispecific discovery approach together with AbbVie’s global oncology research and development expertise to identify and potentially…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com20
- themarketsdaily.com18
- theglobeandmail.com16
- seekingalpha.com14
- tradingview.com9
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.